Thyrocare Q4 PAT Surges 128% YoY to ₹48.70 Cr

Thyrocare reported Q4FY26 consolidated revenue of ₹223.95 crore, up 20% YoY, with PAT surging 128% to ₹48.70 crore.
The company processed 59.0 million tests in Q4FY26, a 29% YoY increase, maintaining its position as India's largest diagnostic test volume processor.
Thyrocare expanded into genomics with NIPT launch and advanced allergy testing, adding 250+ SKUs on the Phadia platform.
For FY26, consolidated revenue grew 21% YoY to ₹829.04 crore with PAT up 81% to ₹162.85 crore.